News & Events
FEATURED
Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology
Co-led by DCVC and a16z, this funding will support the advancement of Vesta, world's first AI test to predict treatment response in bladder cancer, and catalyze expansion in other cancers.
Blog
May 2024
View Article
View Article
Upcoming Events
No items found.